Metropolis Healthcare Ltd Q1 FY27 Earnings Call: Margins Expand 210 bps, Targets 500 Net Centers

Metropolis Healthcare Ltd held its Q1 FY27 earnings call on August 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Strong Volume-Led Beat; Margins Expand 210 bps

• Q1 FY 2026-2027 revenue of Rs.2,450 Cr — grew 17% YoY, driven by 10% patient volume growth and 11% test volume growth; no price increases taken in the period.
• EBITDA of Rs.113 Cr — up 27% YoY, with margin expanding 210 bps to 25.2%, exceeding the FY 2026-2027 guidance of 100-150 bps expansion.
• PAT of Rs.57 Cr — grew 26% YoY, with PAT margin improving 90 bps to 12.6%.
• B2C revenue grew 18% — and B2B revenue grew 15% in Q1 FY 2026-2027; wellness (True Health) grew 22% and specialty grew 17%.
• Q1 revenue outperformed the full-year guidance of 14-15%, which management attributed to a combination of execution in under-penetrated markets and seasonal momentum, though it noted difficulty in fully dissecting the cause.

FY 2026-2027 Revenue Guidance Reaffirmed; Margin Trajectory Intact

• Revenue growth guidance of 14-15% for FY 2026-2027 — reiterated by management, driven by 9-10% patient volume growth and 5-6% product mix improvement; guidance held despite a strong Q1 beat.
• EBITDA margin expansion of 100-150 bps for FY 2026-2027 — guided by management, supported by productivity gains and operating leverage; medium-term target of 27-28% over FY 2026-2027 and FY 2027-2028.
• No price hike taken in FY 2026-2027 — management chose to pass on the GST benefit to consumers; a potential price increase is implied for FY 2027-2028 to pass on cost inflation.
• Capex guided at ~Rs.65 Cr for FY 2026-2027 — consistent with the FY 2025-2026 spend of Rs.65 Cr, including acquired entities.
• Management cited climate change making weather patterns unpredictable, which heavily influences disease testing demand, as a difficulty in forecasting.

500 Net Centers Targeted; Tier 2/3 Push Continues

• 300 gross centers added in Q1 FY 2026-2027 — offset by an equal number of closures from a rationalization exercise in tier 2/3 towns, resulting in a flat net count; net addition target of 500 centers for the full fiscal year.
• Net addition target of 400-500 centers in Tier 2/3 towns for FY 2026-2027 — with 200-250 new centers per quarter expected to drive volume growth.
• Center-to-laboratory ratio improved to 1:21 — in Q1 FY 2026-2027, with a target of 1:30 by end of FY 2026-2027; management sees no further major lab rationalization in FY 2026-2027.
• North India contributes 18% of revenue — up from single digits pre-acquisition, growing 19% YoY in Q1 FY 2026-2027, making it the fastest-growing region.
• Network rationalization is an infrequent exercise (once every 12-18 months) and is not expected to continue every quarter; recent closures had no revenue impact.

Wellness and Specialty Drive Mix; True Health Margins In-Line

• Specialty portfolio at 40% of Q1 FY 2026-2027 revenue — growing 17% YoY; management targets increasing contribution to 45% over time, supported by a test menu of >2,200 tests.
• Wellness (True Health) grew 22% in Q1 FY 2026-2027 — now 18% of revenue; management introduced "True Health Mind & Body," a screening initiative combining blood tests, basic radiology, and cognitive assessments, though no specific revenue targets were provided.
• True Health's average ticket size is Rs.2,500 — and its margins are already in line with the company's overall margins for FY 2026-2027.
• Realisation growth of 5-6% in Q1 FY 2026-2027 — entirely driven by mix shift toward higher-value wellness and specialty tests, with no price increase taken.
• Wellness traction is currently concentrated in tier 1/2 cities but is gaining momentum in deeper tier 2/3 towns, following a sequential pattern: routine, semi-specialty, specialty, then wellness.

Core Diagnostics Margin Target of 25% in 3-4 Years; Bolt-Ons in View

• Core Diagnostics reported high single-digit margins in Q1 FY 2026-2027 — management reiterated its target to bring Core's margins to 25% within 3-4 years of the acquisition (by approximately FY 2028-2029).
• Core's FY 2026-2027 expected EBITDA implies an effective acquisition multiple of ~10x EBITDA — management stated both Core and True Health will be accretive to EBITDA growth over the next few years.
• Management is open to bolt-on acquisitions — targeting strong consumer brands with ethical practices, good science, positive unit economics, and disciplined valuation; also open to larger EPS-accretive deals if the right value can be found and turned around.
• Acquisitions of Dr. Dangs (Dehradun) and Scientifica (Agra) completed — towards the end of Q1 FY 2026-2027, with numbers now consolidated.
• GLP-1 impact on diagnostics is still early days with potential to play out over a longer time frame; tests required for pre-GLP-1 prescriptions are common and difficult to isolate as specific to GLP-1 trends for Q1 FY 2026-2027.

Unorganized-to-Organized Shift Slow; CGHS Contribution Small

• Shift from unorganized to organized players described as "slow and steady" — management noted anecdotally that volume growth at smaller labs is slower, with no catalyst for a sudden marked change (e.g., from 10-15% organized to 30%).
• Only 10% of India's ~3 lakh labs run by MD pathologists — management noted that 90% are run by technicians, influencing the type of tests outsourced to organized players.
• CGHS revenue is ~1% of total business — management confirmed the recent CGHS price revision provides a benefit on this small base, but the impact is not material compared to peers.
• B2B competition described as normal intensity — management noted many entrants reach Rs.50-75 Cr in annual revenue but fail to scale profitably.
• Management cited "government targeting 100% insurance penetration by 2047" as a long-term TAM driver, but noted the pace of organized shift remains gradual.